Hayward, United States
Arcus Biosciences, founded in 2015, stands at the forefront of the biopharmaceutical industry, specializing in the creation of precision combination medicines aimed at extending the lives of cancer patients. As a clinical-stage global entity headquartered in the United States, the company is strategically positioned in the San Francisco bay area, a hub for innovation and biotech development.
Emphasizing its motto of being a "Global, biopharmaceutical company at the forefront of designing precision combinations in the pursuit of cures," Arcus Biosciences is committed to tackling cancer treatment by addressing areas of high unmet medical need. They cultivate an exceptionally dynamic, team-driven work environment, incentivizing innovation through stock options and a competitive benefits package.
In 2025, the company secured a substantial $287.50M in Post-IPO Equity investment, indicating strong confidence from the financial markets in its mission and growth trajectory. Investors looking for a formidable player in the biopharma space may find Arcus Biosciences a promising opportunity.
Orum Therapeutics
Mersana Therapeutics
Biocon
